The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment - Ariceta Iraola, Gema (Hospital Universitari Vall d'Hebron) ; Dixon, B.P. (Renal Section. Department of Pediatrics. University of Colorado School of Medicine) ; Kim, S.H. (Department of Pediatrics. Pusan National University Children's Hospital) ; Kapur, G. (Faculty of Pediatric Sciences. Central Michigan University. Mount Pleasant) ; Mauch, T. (Department of Nephrology and Hypertension. Division of Pediatrics. University of Utah) ; Ortiz, S. (Clinical and Non-Clinical Pharmacology. Alexion Pharmaceuticals Inc.) ; Vallee, M. (Biostatistics. Alexion Pharmaceuticals Inc.) ; Denker, A.E. (Clinical Development. Alexion Pharmaceuticals Inc.) ; Kang, H.G. (Division of Pediatric Nephrology. Department of Pediatrics. Seoul National University College of Medicine) ; Greenbaum, L.A. (Division of Pediatric Nephrology. Emory University School of Medicine and Children's Healthcare of Atlanta) ; Lovell, H. ; Muff-Luett, M. ; Malone, K. ; Adeagbo, O. ; Wilkerson, A. ; Fraga Rodríguez, Gloria María (Institut d'Investigació Biomèdica Sant Pau) ; Sarri, S. ; Cheong, H.I. ; Ahn, Y.H. ; Han, K.H.
 
Comentaris (0) | Ressenyes (0)
Sigueu el primer a escriure una ressenya d'aquest document.

Afegiu la vostra ressenya

Valoreu aquest article:
Doneu un títol a la vostra ressenya:
Escriviu la vostra ressenya:
Vigileu: encara no heu definit el vostre àlies.
N/D s'usarà temporalment com a autor d'aquest comentari.